mRNA-1653

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Phase 1

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

CompletedNCT03392389

ModernaTX, Inc.Human Metapneumovirus and Human Parainfluenza Infection

Start: 2017-12-04End: 2019-07-29Updated: 2020-02-06

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

CompletedNCT04144348

ModernaTX, Inc.Human Metapneumovirus and Human Parainfluenza Infection

Start: 2019-11-04End: 2022-12-20Updated: 2023-02-03

Related Papers

2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children

Open Forum Infectious Diseases2023-11-275 citations